Status:
COMPLETED
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis
Lead Sponsor:
GlaxoSmithKline
Conditions:
Vasomotor Rhinitis
Rhinitis, Vasomotor
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Must be outpatients.
- Diagnosis of VMR (vasomotor rhinitis).
- Literate in English or native language.
- Exclusion criteria:
- Significant concomitant medical condition.
- Use corticosteroids or other allergy medications during the study.
- Used tobacco products within the past year.
Exclusion
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 9 2006
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00118703
Start Date
July 1 2005
End Date
February 9 2006
Last Update
August 21 2017
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Birmingham, Alabama, United States, 35209
2
GSK Investigational Site
Phoenix, Arizona, United States, 85012
3
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
4
GSK Investigational Site
Fresno, California, United States, 93720